Agilent will be participating in the American Society of Clinical Oncology (ASCO) Annual Meeting, where the company will highlight its companion diagnostics (CDx) capabilities and broad technology portfolio supporting precision medicine. With deep expertise spanning early assay development through CDx commercialization, and a global infrastructure designed to support regulated diagnostics programs, Agilent works with many of the world’s leading pharmaceutical companies to advance personalized medicine.

---

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

Agilent announces the launch of its latest innovation in liquid chromatography (LC)-mass detection: the Agilent InfinityLab Pro iQ Series. This groundbreaking series includes the InfinityLab Pro iQ and the InfinityLab Pro iQ Plus, each tailored with distinct features and capabilities to meet the diverse analytical needs of modern laboratories.

View press release

---

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

Agilent announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

View press release

---